TY  - GEN
AU  - Persson,U
AU  - Willis,M
AU  - Odegaard,K
AU  - Apelqvist,J
TI  - The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data
SN  - 1524-4733
PY  - 2007///1026
KW  - Aged
KW  - Angiogenesis Inducing Agents
KW  - economics
KW  - Becaplermin
KW  - Cost-Benefit Analysis
KW  - methods
KW  - Diabetic Foot
KW  - classification
KW  - Humans
KW  - Markov Chains
KW  - Middle Aged
KW  - Platelet-Derived Growth Factor
KW  - Proto-Oncogene Proteins c-sis
KW  - Severity of Illness Index
KW  - Sweden
KW  - Treatment Outcome
KW  - United States
KW  - Wound Healing
KW  - drug effects
N1  - Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1046/j.1524-4733.2000.36027.x
ER  -